Hepatocellular carcinoma (HCC) Cancer
Conditions
Interventions
A total of 144 patients were randomly assigned to either the DEB-TACE group or the conventional lipiodol (cTACE) group using a computer-generated randomization sequence. The allocation ratio was 1:1.
Sponsors
Beijing YouAn Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed diagnosis of HCC 2. No previous treatment for HCC 3. No contraindications for surgery, liver transplantation, or local ablation 4. No previous treatment with chemotherapy or targeted therapy for HCC 5. No history of radiation therapy for HCC 6. No history of radioembolization for HCC 7. No history of radiofrequency ablation for HCC 8. No history of percutaneous ethanol injection for HCC
Exclusion criteria
Exclusion criteria: Patients who had received any of the above treatments within 6 months before enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Serum AFP level measured by enzyme-linked immunosorbent assay at baseline and after 3 months and 12 months follow-up 2. Tumor morphology measured using multidetector computed tomography (MDCT) or magnetic resonance imaging (MRI) evaluation at baseline and after 3 months and 12 months follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
China
Contacts
Public ContactGuangming Li
Outcome results
None listed